"Targeting cancer drugs to the tumor for improved patient outcomes"
VAST is an innovative small molecule discovery platform with unique 3D compound shapes that expand chemical diversity.
Audeo is a late-stage, oncology focused biopharmaceutical company with an integrated pipeline of products stemming from two core technology platforms
Currently in a pivotal Phase III trial in mCRC with top line data expected in H1-CY 2014.
Audeo Oncology manages a late-stage oncology pipeline which includes HA-Irinotecan in Phase III clinical trial
HyACT is a flexible platform technology that we are using to target cancer drugs directly to tumors. More...
Wants more information about Audeo, our products or investing?